Tilmann Brotz
About Tilmann Brotz
Dr. Tilmann Brotz is a seasoned neuroscientist and head of preclinical development, with extensive experience in drug development and leadership roles in various biotechnology companies.
Tilmann Brotz - Title and Current Position
Tilmann Brotz is the Head of Preclinical Development. He has an extensive background in neuroscience and drug development, leading disciplines such as toxicology, DMPK, in-vivo pharmacology, clinical pharmacology, and diagnostic groups. His current role capitalizes on over 20 years of experience in these specialized fields.
Tilmann Brotz - Professional Background
Dr. Brotz has a wealth of experience in neuroscience and drug development. Most recently, he served as Sr. Director, Development Sciences at Achaogen. During his tenure, he contributed to multiple programs ranging from lead optimization through Phase 3. Prior to Achaogen, he functioned as head of preclinical development and worked as a consultant for several emerging companies, providing expert guidance on their development projects.
Tilmann Brotz - Advisory Roles
In addition to his professional roles, Dr. Brotz serves as an advisor for the CLSI FAST Program, where he lends his expertise in the field of preclinical development. He is also a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation, playing a key role in evaluating scientific proposals and research initiatives.
Tilmann Brotz - Academic Background
Dr. Tilmann Brotz holds a PhD in Neuroscience from the University of Tübingen. His academic background laid the foundation for his extensive career in drug development and neuroscience, equipping him with deep expertise and a comprehensive understanding of the field.